Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moses S Elisaf

Showing results (71-80 of 198) with videos related to

Pageof 20
Sort By:
Clinical Pharmacology : Advances and Applications|October 2, 2019
Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetesIoanna Papakitsou, George Vougiouklakis, Moses S Elisaf, et al.
Postgraduate Medicine|February 14, 2019
SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypothesesTheodosios D Filippatos, Angelos Liontos, Ioanna Papakitsou, et al.
Expert Opinion on Emerging Drugs|October 31, 2014
Emerging drugs for hyperlipidaemia: an updateMatilda Florentin, Michael S Kostapanos, Anastazia Kei, et al.
Clinical Interventions in Aging|November 29, 2017
Hyponatremia in the elderly: challenges and solutionsTheodosios D Filippatos, Andromachi Makri, Moses S Elisaf, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|February 8, 2018
Hypolipidemic Drugs and Diabetes Mellitus-Mechanisms and Data From Genetic TrialsTheodosios D Filippatos, Thalia Panagiotopoulou, Eleftheria Tzavella, et al.
Vascular Health and Risk Management|August 24, 2010
Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acidElisavet Moutzouri, Anastazia Kei, Moses S Elisaf, et al.
Postgraduate Medicine|March 18, 2017
Serum osmolal gap in clinical practice: usefulness and limitationsGeorge Liamis, Theodosios D Filippatos, Angelos Liontos, et al.
Metabolism: Clinical and Experimental|February 7, 2012
A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular diseaseAnastazia A Kei, Theodosios D Filippatos, Vasilios Tsimihodimos, et al.
Expert Opinion on Drug Safety|November 6, 2008
Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortalityEvangelos N Liberopoulos, Matilda Florentin, Dimitri P Mikhailidis, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|August 23, 2017
Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid VariablesTheodosios D Filippatos, Anastazia Kei, Christos V Rizos, et al.
Pageof 20

Showing results (71-80 of 198) with videos related to

Sort By:
Pageof 20
Clinical Pharmacology : Advances and Applications|October 2, 2019
Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetesIoanna Papakitsou, George Vougiouklakis, Moses S Elisaf, et al.
Postgraduate Medicine|February 14, 2019
SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypothesesTheodosios D Filippatos, Angelos Liontos, Ioanna Papakitsou, et al.
Expert Opinion on Emerging Drugs|October 31, 2014
Emerging drugs for hyperlipidaemia: an updateMatilda Florentin, Michael S Kostapanos, Anastazia Kei, et al.
Clinical Interventions in Aging|November 29, 2017
Hyponatremia in the elderly: challenges and solutionsTheodosios D Filippatos, Andromachi Makri, Moses S Elisaf, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|February 8, 2018
Hypolipidemic Drugs and Diabetes Mellitus-Mechanisms and Data From Genetic TrialsTheodosios D Filippatos, Thalia Panagiotopoulou, Eleftheria Tzavella, et al.
Vascular Health and Risk Management|August 24, 2010
Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acidElisavet Moutzouri, Anastazia Kei, Moses S Elisaf, et al.
Postgraduate Medicine|March 18, 2017
Serum osmolal gap in clinical practice: usefulness and limitationsGeorge Liamis, Theodosios D Filippatos, Angelos Liontos, et al.
Metabolism: Clinical and Experimental|February 7, 2012
A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular diseaseAnastazia A Kei, Theodosios D Filippatos, Vasilios Tsimihodimos, et al.
Expert Opinion on Drug Safety|November 6, 2008
Compliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortalityEvangelos N Liberopoulos, Matilda Florentin, Dimitri P Mikhailidis, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|August 23, 2017
Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid VariablesTheodosios D Filippatos, Anastazia Kei, Christos V Rizos, et al.
Pageof 20